Richard Chin Net Worth

The estimated Net Worth of Richard Chin is at least $20.1 Million dollars as of 2 August 2021. Richard Chin owns over 40,000 units of Kindred Biosciences Inc stock worth over $14,192,007 and over the last 11 years Richard sold KIN stock worth over $5,880,610.

Richard Chin KIN stock SEC Form 4 insiders trading

Richard has made over 23 trades of the Kindred Biosciences Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Richard sold 40,000 units of KIN stock worth $368,400 on 2 August 2021.

The largest trade Richard's ever made was selling 52,610 units of Kindred Biosciences Inc stock on 30 May 2018 worth over $531,361. On average, Richard trades about 18,431 units every 42 days since 2014. As of 2 August 2021 Richard still owns at least 1,534,271 units of Kindred Biosciences Inc stock.

You can see the complete history of Richard Chin stock trades at the bottom of the page.

What's Richard Chin's mailing address?

Richard's mailing address filed with the SEC is C/O KINDRED BIOSCIENCES, INC., 1555 BAYSHORE HIGHWAY, SUITE 200, BURLINGAME, CA, 94010.

Insiders trading at Kindred Biosciences Inc

Over the last 11 years, insiders at Kindred Biosciences Inc have traded over $10,542,886 worth of Kindred Biosciences Inc stock and bought 50,952,388 units worth $461,948,778 . The most active insiders traders include Animal Health Inc Elanco, West Asset Management Llc Park, and Ernest Mario. On average, Kindred Biosciences Inc executives and independent directors trade stock every 34 days with the average trade being worth of $5,949,674. The most recent stock trade was executed by Animal Health Inc Elanco on 27 August 2021, trading 45,508,938 units of KIN stock currently worth $420,957,677.

What does Kindred Biosciences Inc do?

Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated targets for dogs and cats. KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio.

Complete history of Richard Chin stock trades at Kindred Biosciences Inc

Kindred Biosciences Inc executives and stock owners

Kindred Biosciences Inc executives and other stock owners filed with the SEC include:

• Krystian Dejk,
  Chairman of the Management Board
• Halina Kleba,
  Member of the Supervisory Board
• Bartlomiej Weglewski,
  Chairman of the Supervisory Board
• Krzysztof Kochanowski,
  Member of the Supervisory Board
• Hanna Smolinska,
  Member of the Supervisory Board
• Lukasz Cieslak,
  Member of the Supervisory Board
• Raymond Townsend,
  Director
• Ernest Mario,
  Director
• Stephen Sundlof,
  SVP of Regulatory Affairs
• Ervin Veszpremi,
  Director
• Herbert D Montgomery,
  Director
• West Asset Management Llc Park,
  10% owner
• Wendy Wee,
  Chief Financial Officer
• Hangjun Zhan,
  Chief Scientific Officer
• Denise Bevers,
  Director
• Selby Blake Hawley,
  Chief Commercial Officer
• Joseph S Mc Cracken,
  Director
• Oleg Nodelman,
  Director
• Kevin Schultz,
  Chief Scientific Officer
• Stephen S Galliker,
  Chief Financial Officer
• Richard Chin,
  Chief Executive Officer
• Lyndon Lien,
  Director
• Nanxi Liu,
  Director
• Animal Health Inc Elanco,
  10% owner